M2 PHARMA-February 8, 2018-Europe, Japan, and Hong Kong Issue Patents to Biocept for
Target Selector Platform
Biocept announces the issuance of patents in Europe, Japan and Hong Kong for its core
Target Selector liquid biopsy technology.
This is the second issued patent for Biocept's
Target Selector assays for molecular analysis using real-time PCR, Sanger sequencing and next generation sequencing (NGS).
This agreement allows Teneovita to market and distribute Biocept's
Target Selector liquid biopsy testing services to major cancer hospitals, individual oncology practices, and integrative oncology centers.
We are pleased that patients with Wellmark will now have in-network access to our highly sensitive
Target Selector platform.
Biocept's
Target Selector liquid biopsy tests are performed in its laboratory located in San Diego, California.
Molecular diagnostics company Biocept (NasdaqCM:BIOC) said on Wednesday that it has unveiled its proprietary quantitative
target selector assay targeting KRAS mutations utilising a patient's blood sample.
Assistant Professor at UCSD School of Medicine, the 100-patient study is designed to clinically validate Biocept's
Target Selector PD-L1 assay for patients diagnosed with non-small cell lung cancer (NSCLC).
Biocept now offers 15 CLIA-certified liquid biopsy tests utilizing its
target selector platform to determine the status of key cancer biomarkers listed in the The National Comprehensive Cancer Network (NCCN) Guidelines.
Biocept's
Target Selector liquid biopsy tests are performed in its CLIA-certified, CAP-accredited laboratory located in San Diego, California.
The study is designed to evaluate the clinical utility of Biocept's
target selector platform for patients diagnosed with ALK-positive non-small cell lung cancer (NSCLC) and treated with ALK-inhibitor therapy.
Biocept's patented
Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells and in circulating tumor DNA (ctDNA).
